Lake Street Maintains Inotiv at Buy, Cuts Price Target to $5

Summary

Lake Street maintains its buy rating for Inotiv but adjusts the target price from $6.00 to $5.00. Inotiv Inc is a drug development company focused on the pharmaceutical, chemical, and medical device industries, providing non-clinical analysis services through its Discovery & Safety Assessment (DSA) and Research Models & Services (RMS) segments, with RMS being the primary revenue source.Stock Star

Impact Analysis

This event is at the company level, impacting Inotiv directly. Lake Street’s adjustment in price target reflects a revaluation of the company’s expected stock performance. Despite maintaining a buy rating, the lowered target price suggests increased caution due to factors like earnings expectations or industry conditions. Inotiv’s recent financial results showed a 4.4% revenue increase to $124.3 million, but analysts estimate a loss of 63 cents per share, which could influence investor sentiment negatively.Reuters+ 2 Investors should consider the company’s revenue growth potential against the backdrop of analyst loss estimates and recalibrated target price when assessing investment opportunities or risks.